711 related articles for article (PubMed ID: 24229770)
41. Validation of FDG uptake in the arterial wall as an imaging biomarker of atherosclerotic plaques with 18F-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT).
Bucci M; Aparici CM; Hawkins R; Bacharach S; Schrek C; Cheng S; Tong E; Arora S; Parati E; Wintermark M
J Neuroimaging; 2014; 24(2):117-23. PubMed ID: 22928741
[TBL] [Abstract][Full Text] [Related]
42. PERISCOPE: pioglitazone offers the right cluster of effects to confer benefit in type 2 diabetes.
Cardiovasc J Afr; 2008; 19(3):159-62. PubMed ID: 18568180
[No Abstract] [Full Text] [Related]
43. Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: a randomized prospective study using intravascular ultrasound.
Nakayama T; Komiyama N; Yokoyama M; Namikawa S; Kuroda N; Kobayashi Y; Komuro I
Int J Cardiol; 2010 Jan; 138(2):157-65. PubMed ID: 18817993
[TBL] [Abstract][Full Text] [Related]
44. Impact of glitazones on metabolic and haemodynamic parameters in patients with type 2 diabetes mellitus.
Chogtu B; Singh NP; Chawla S; Gupta U
Singapore Med J; 2009 Apr; 50(4):395-9. PubMed ID: 19421684
[TBL] [Abstract][Full Text] [Related]
45. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
Derosa G; Maffioli P; Ferrari I; Mereu R; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Salvadeo SA
Horm Metab Res; 2010 Aug; 42(9):663-9. PubMed ID: 20560108
[TBL] [Abstract][Full Text] [Related]
46. Systemic Atherosclerotic Inflammation Following Acute Myocardial Infarction: Myocardial Infarction Begets Myocardial Infarction.
Joshi NV; Toor I; Shah AS; Carruthers K; Vesey AT; Alam SR; Sills A; Hoo TY; Melville AJ; Langlands SP; Jenkins WS; Uren NG; Mills NL; Fletcher AM; van Beek EJ; Rudd JH; Fox KA; Dweck MR; Newby DE
J Am Heart Assoc; 2015 Aug; 4(9):e001956. PubMed ID: 26316523
[TBL] [Abstract][Full Text] [Related]
47. Effect of pioglitazone on inflammation and calcification in atherosclerotic rabbits : An
Xu J; Nie M; Li J; Xu Z; Zhang M; Yan Y; Feng T; Zhao X; Zhao Q
Herz; 2018 Dec; 43(8):733-740. PubMed ID: 28956073
[TBL] [Abstract][Full Text] [Related]
48. The IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions.
Karagiannis E; Pfützner A; Forst T; Lübben G; Roth W; Grabellus M; Flannery M; Schöndorf T
Diabetes Technol Ther; 2008 Jun; 10(3):206-12. PubMed ID: 18473695
[TBL] [Abstract][Full Text] [Related]
49. A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study).
Takagi T; Okura H; Kobayashi Y; Kataoka T; Taguchi H; Toda I; Tamita K; Yamamuro A; Sakanoue Y; Ito A; Yanagi S; Shimeno K; Waseda K; Yamasaki M; Fitzgerald PJ; Ikeno F; Honda Y; Yoshiyama M; Yoshikawa J;
JACC Cardiovasc Interv; 2009 Jun; 2(6):524-31. PubMed ID: 19539256
[TBL] [Abstract][Full Text] [Related]
50. A multicenter, phase III evaluation of the efficacy and safety of a new fixed-dose pioglitazone/glimepiride combination tablet in Japanese patients with type 2 diabetes.
Hiroi S; Sugiura K; Matsuno K; Hirayama M; Kuriyama K; Kaku K; Kawakami K
Diabetes Technol Ther; 2013 Feb; 15(2):158-65. PubMed ID: 23289434
[TBL] [Abstract][Full Text] [Related]
51. Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes.
Matsubara J; Sugiyama S; Akiyama E; Iwashita S; Kurokawa H; Ohba K; Maeda H; Fujisue K; Yamamoto E; Kaikita K; Hokimoto S; Jinnouchi H; Ogawa H
Circ J; 2013; 77(5):1337-44. PubMed ID: 23386232
[TBL] [Abstract][Full Text] [Related]
52. Role of FDG PET-CT in Takayasu arteritis: sensitive detection of recurrences.
Tezuka D; Haraguchi G; Ishihara T; Ohigashi H; Inagaki H; Suzuki J; Hirao K; Isobe M
JACC Cardiovasc Imaging; 2012 Apr; 5(4):422-9. PubMed ID: 22498333
[TBL] [Abstract][Full Text] [Related]
53. Coronary arterial 18F-FDG uptake by fusion of PET and coronary CT angiography at sites of percutaneous stenting for acute myocardial infarction and stable coronary artery disease.
Cheng VY; Slomka PJ; Le Meunier L; Tamarappoo BK; Nakazato R; Dey D; Berman DS
J Nucl Med; 2012 Apr; 53(4):575-83. PubMed ID: 22419753
[TBL] [Abstract][Full Text] [Related]
54. The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: a multicenter FDG-PET trial.
Emami H; Vucic E; Subramanian S; Abdelbaky A; Fayad ZA; Du S; Roth E; Ballantyne CM; Mohler ER; Farkouh ME; Kim J; Farmer M; Li L; Ehlgen A; Langenickel TH; Velasquez L; Hayes W; Tawakol A
Atherosclerosis; 2015 Jun; 240(2):490-6. PubMed ID: 25913664
[TBL] [Abstract][Full Text] [Related]
55. Identification of inflamed atherosclerotic lesions in vivo using PET-CT.
Jezovnik MK; Zidar N; Lezaic L; Gersak B; Poredos P
Inflammation; 2014 Apr; 37(2):426-34. PubMed ID: 24282108
[TBL] [Abstract][Full Text] [Related]
56. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study.
Tawakol A; Fayad ZA; Mogg R; Alon A; Klimas MT; Dansky H; Subramanian SS; Abdelbaky A; Rudd JH; Farkouh ME; Nunes IO; Beals CR; Shankar SS
J Am Coll Cardiol; 2013 Sep; 62(10):909-17. PubMed ID: 23727083
[TBL] [Abstract][Full Text] [Related]
57. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R
Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
[TBL] [Abstract][Full Text] [Related]
58. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.
Mattoo V; Eckland D; Widel M; Duran S; Fajardo C; Strand J; Knight D; Grossman L; Oakley D; Tan M;
Clin Ther; 2005 May; 27(5):554-67. PubMed ID: 15978304
[TBL] [Abstract][Full Text] [Related]
59. Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis.
Elkhawad M; Rudd JH; Sarov-Blat L; Cai G; Wells R; Davies LC; Collier DJ; Marber MS; Choudhury RP; Fayad ZA; Tawakol A; Gleeson FV; Lepore JJ; Davis B; Willette RN; Wilkinson IB; Sprecher DL; Cheriyan J
JACC Cardiovasc Imaging; 2012 Sep; 5(9):911-22. PubMed ID: 22974804
[TBL] [Abstract][Full Text] [Related]
60. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
Umpierrez G; Issa M; Vlajnic A
Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
